Conference

Contact us


Speaker Introduction

Subject
Next Generation Environmental Friendly Antibiotics

Ada Yonath
Professor, Department of Structural Biology,Weizmann Institute

Subject
Take the clinic needs as the core to accelerate the innovative development of biomedicine

Chenyan GAO
Head of Biologics Clinic Dept, CFDA-CDE

Subject
Precision Medicine: Fuel the Momentum to Drive a Healthier China

Gianluca Pettiti
President, Greater China, Thermo Fisher Scientific China

Subject
A Coherent Approach to Drug and Biomarker Discovery and Development

Kerry L.Blanchard
Senior Vice president of External Innovation, Eli Lilly and Company

Mingde XIA
Senior Director of Johnson & Johnson Innovation APIC

Subject
Current Status and Future of Medical Sciences in China

Xuetao CAO
President of Chinese Academy of Medical Sciences and Peking Union Medical College

Subject
Current?Status?and?Development?of?Nature Product Based Drugs R&D in?China

Zixin DENG

Joe ZHOU
CEO,Genor Biopharma Co. Ltd.

Bin WANG
professor,Director,Institutes of Biomedical Sciences Fudan University, Fudan University Shanghai Medical College

Hongwei PENG
Vice-President, Chairman,Genenkey Biotech(Chengdu)Co.,Ltd , China Protein Drug Quality Alliance

Subject
Therapeutic antibody development for non-oncology targets

Hua YING
Senior Director of Biologics, Shanghai Hengrui R&D center

Subject
Vaccine Development for Major Global Health Needs

Jiande SHU
CEO, Sanofipasteur (China)

Subject
Immunization with Heterogous HIV Env Immunogens Raises Broadcross-Reactive Neutralization Antibodies

Jianqing XU
Deputy Director,Shanghai Public Health Clinical Center,Institutes of Biomedical Sciences Fudan University

Li SHI
currently leading Zerun Bio focusing on human vaccine development and commercialization

Subject
Immunologic approaches to HIV cure

Lishan SU
Professor,University of North Carolina-Chapel Hill

Subject
From Reproductive Safety to Drug Development: Use of Embryonic Stem Cell Screening Paradigms

Richard H. Finnell
Professor of Pediatrics, Dell Pediatric Research Institute, The University of Texas at Austin

Subject
Safe and Effective MERS-CoV Vaccine Development

Shibo JIANG
Director, Fudan University Shanghai Medical College

Subject
Development of Biosimilars in China

Shigao LIU
President & CEO,Shanghai Henlius Biotech Inc

Subject
Study on Long Term Protective Mechanism of Hepatitis A Vaccine

Xuanyi WANG
Deputy Director,Institutes of Biomedical Sciences Fudan University,National Engineering Laboratory for Therapeutic Vaccines

Jason LIU

Jason JIN
CLOUD HEALTH CEO

Jinhai SHI
Vice Dean, Secretary-General, Tianjin International Joint Academy of Biomedicine, China Protein Drug Quality Alliance

Subject
Construction of Information and technology platforms for regional Life & healthcare industry development

Hongxing NIU
Deputy Director, Industry Development Department at Deputy Director, Industry Development Department

Subject
我国生物药十三五发展的重点和趋势

Junzhi WANG
Professor, Chief Expert for Biologicals Analysis, National Institutes for Food and Drug Control

Li JIN

Subject
Development Trends of Global Biologics Market: Opportunities for CDMO Players in China

Ji ZHANG
CEO, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd

Xia JIN
Professor, Institut Pasteur of Shanghai, Chinese Academy of Sciences

Subject
Discussion of BE Study

Chen YU
Head of Phase I Clinical Dept and GCP office,Shanghai Xuhui Central Hospital / Zhongshan- Xuhui Hospital,Fudan UniversityShanghai Clinical Center, CAS

Subject
Drug Development & Regulatory Strategy Under ICH

Dan ZHANG
President, Fountain Medical Development Ltd.

Guang NI

Subject
Current Challenges of Innovative Drug Development in China and in US

Guoliang YU
President, CrowmBio

Subject
Clinical needs and technology progress of minimally invasive treatment

Henry NIE
President ,Ezisurg Medical Co., Ltd

Lifang ZHANG
Honorary Director ,Shanghai Medical Association Clinical Engineering Branch

Subject
Lessons from Basic Research in Targeting Signaling Pathways

Xinhua FENG
Professor, Life Sciences Institute Zhejiang University

Yang LU
President and CSO, Suzhou Sirnaomics Biopharmaceuticals Co.,Ltd.

Subject
Common consideration on quality control in the evaluation of pharmaceutical equivalence of generic drugs

Yongjian YANG
Head of Chemical Drugs Dept,Shanghai Institute for Food and Drug Control

Subject
Polymer Microneedles for Drug and Vaccine Delivery

Xindong GUO
professor,College of Materials Science and Engineering, Beijing University of Chemical Technology

Subject
Initial R&D of oral subunit triple vaccine (LTm@EVS) preparation for epidemic bacterial diarrhea

Xingyuan MA
Prof./ PI,Director of Biomedical Lab,State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China

Subject
Outlook of Precision Medicine Development and Livzon’s Strategies

Daotian FU
Vice President,Livzon Pharmaceuticals Group

Subject
Protein Engineering of an Arginine Deiminase for Anti-Tumor Application

Leilei ZHU
Group leader,Tianjin Institute of Industrial Biotechnology

Subject
Delivering R&D Excellence in China

Mingqiang ZHANG
VP R&D,Amgen BioPharmaceutical R&D (Shanghai) Co., Ltd.

Subject
Progress?of?novel?vaccine?for?chronic?non-communicable?disease

Rongxiu LI
Professor,Shanghai?Jiao?Tong?University

Subject
Biopharmaceutical Manufacturing Vision of the Future

Shoubo CHAO
Senior Vice President, BioVentures, AstraZeneca

Subject
Analysis and Solution to Obstructions of Downstream Process

Tao JIANG
Senior engineer, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences

Subject
Targeting human gammadelta-T cells to control influenza and EBV infections

Wenwei TU
Director,Li Ka Shing Faculty of Medicine, The University of Hong Kong

Subject
Next Generation of Immune Checkpoint Inhibitors

Wenzhi TIAN
Founder, Chairman & CEO,ImmuneOnco Biopharma CO., Ltd

Subject
Biomarker and CDx in Precision Medicine

Yafei ZHANG
CEO, Qiagen Suzhou Translational Medicine

Yibiin SHI

Subject
Key Points and Concerns of Allergy Test on Vaccines

Yihong TIAN
Chief Technology Officer of the GLP Department ,TIPR Drug Assessment Co.Ltd

Subject
The impact of key ingredients on product quality

Youling WU
CEO/Chairman of the board , Zhejiang Teruisi Pharmaceutical Inc.

Subject
QbD: Allotypes of Therapeutic mAbs

Ziyi KAN
Chief Technology Officer & Head of Quality, Genor BioPharma Co., Ltd.

Subject
Recent Advances on Suturing Devices for Minimally Invasive Surgery

Chengli SONG
Professor, Executive Director,University of Shanghai for Science and Technology

Subject
Novel isoelectric focusing techniques and instruments for protein drug analyses and purification

Chengxi CAO
Head of Bioseparation-Analytical Biochemistry Laboratory, Shanghai Jiao Tong University

Chungui Gong
Director, Department of Medical Equipment ,Shanghai Eastern Hepatobiliary Surgery Hospital

Subject
The path from bench to bedside :successful development of quality cell products

Fan YANG
Principal Scientist,Cell Therapy Development Services ,Lonza INC

Subject
Minimally invasive diagnosis and treatment industry analysis report

Hongfei YANG
CEO,Firestone

Subject
Technology Advances and Trends on Minimally Invasive Medical Devices

Hongyan JIANG
Vice President, Shanghai MicroPort Medical (Group) Co., Ltd.

Subject
Innovation and Integration from Development to Manufacturing to Delivery Affordable New Biologics to Patient

Jerry YANG
SVP, Process & Product Development, Hangzhou Just Biotherapeutics Ltd.

Subject
Application of Quality by Design in Quality Consistency Evaluation on Generic Drug Product

Jian ZHAO
Senior director of PDS, LTD,WuXi AppTec (Shanghai) Co., Ltd.

Subject
A Case Study of Immunogenicity Assessment in a Biosimilar Comparability Study: Impact of Target Interference and Solutions

Jing SHI
Senior director of BAS, LTD,WuXi AppTec (Shanghai) Co., Ltd.

Ju GAO

Subject
Immune Effects of Antibody Drug Conjugates

Mary Chaohong HU
CEO,Shanghai Miracogen Inc.

Subject
Development of Spine MIS Technology

Mingyan LIU
Chairman, Chief Scientist,SHANGHAI SANYOU MEDICAL CO., LTD

Subject
Immunotherapy, Two Sides of A Coin

Richard WANG
CEO,Fosun Kite Biotechnology Co.,Ltd.

Ruiyao JIANG
Deputy Director,Department of Medical Equipment, Shanghai Sixth People’s Hospital

Shaoping CAO
Deputy Director, Shanghai Medical Association Clinical Engineering Branch

Subject
The Advances in Thermal Ablation for Interventional Oncology – Novel Microwave Ablation Technology

Wei ZHANG
Productdevelopment manager,Medtronic China R&D Center

Subject
The Past and the Future of Arthroscopy

Weiguo LAI
Deputy General Manager,Shanghai Kinetic Medical Co., Ltd

Subject
Data Accuracy and Reliability of Clinical Bioanalysis and How to Meet the Requirement of Regulatory Agency’s Inspection

Wenzhong LIANG
Senior director of BAS, LTD, WuXi AppTec (Shanghai) Co., Ltd.

Yu YANG
Senior Product Manager of LTD, WuXi AppTec Co., Ltd.

Subject
Dissolution and Quality Study for Generic Drug Consistency Evaluation

Zhen LIU
Senior Director of ASU, LTD, WuXi AppTec (Shanghai) Co., Ltd.

Subject
The principle and application of 3D imaging system

Zhiqiang CHEN
marketing manager,OLYMPUS

Subject
Global Contract Manufacturing Excellence in China Biopharmaceutical Market

Chelsea Mou
Associate Director, Business Development & Key Account Management, China,Company: Boehringer Ingelheim Biopharmaceutical (China) Co., Ltd.

Jianguo QIAN
Director, Shanghai Medical Association Clinical Engineering Branch

Subject
Development and Clinical Application of Orthopedic Surgical Robot

Jun SHI
Channel Sale Director, TINVAVI Medical Technologies Co., Ltd.

Jun WANG
VP of Discovery Biology ,Shanghai Medicilon Inc.

Subject
A Novel and High Throughput System for Drug Discovery against HIV-1 Multi-protease Inhibitor Resistance

Richard Y. Zhao
Professor,University of Maryland School of Medicine

Subject
Strategy for the Assessment and Control of Fc Effector Function of Therapeutic Antibodies

Xurong JIANG
Director, BioVentures, AstraZeneca

Subject
BE study of Highly variable drug

Zhaoyu LUO
Senior director of Medical affairs, WuXi CDSCo., Ltd.

TOP